ISRCTN93153882终止未知
Evaluating Personalized Prescribing Inc's pharmacogenomic profiling (Rx Report) for optimizing treatment in patients with depressive disorders: an ambulatory-care, delayed-access randomized controlled trial
Personalized Prescribing Inc.0 个研究点目标入组 200 人开始时间: 2022年2月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with newly diagnosed depressive disorder (>9 on the Physical Health Questionnaire Version 9 [PHQ-9] screening at baseline in the last 2 years
- •2. Patients who are on one antidepressant prior to being diagnosed
- •3. Aged between 18 years and 65 years
- •4. Have provided written informed consent
- •5. Have completed sixth grade or higher education in English language to respond to standard questionnaires
排除标准
- •1. Patients on more than two antidepressants at the time of recruitment
- •2. Acute myocardial infarction in the past 12 months
- •3. Traumatic brain injury requiring hospitalization in the past 12 months
- •4. Concussion related emergency or physician visit in the past 5 years
- •5. Suffering from congestive heart failure
- •6. Are pregnant and lactating
- •7. History of epilepsy or seizures
- •8. Uncontrolled hypertension diagnosed by a physician (consistently elevated systolic blood pressure =150 mmHg or diastolic blood pressure =90 mmHg)
- •9. History of concussion in the past 12 months
- •10. History of stroke
- •11. Uncontrolled diabetes (HbA1c >8.0%)
- •12. History of chronic pain
- •13. History of autoimmune condition
- •14. History of Bipolar Disorder
- •15. History of Autism Spectrum Disorder (ASD)
- •16. History of Attention Deficit Hyperactivity Disorder (ADHD)
- •17. History of neurodevelopmental disorder (e.g., intellectual disability)
- •18. History of neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease etc)
- •19. History of Schizophrenia Spectrum Disorder
- •20. History of malignant tumor
- •21. History of liver failure
- •22. History of renal insufficiency
- •23. History of substance misuse treatment
- •24. Consuming alcohol more than three drinks per day for men (=15/week) or two drinks per day for women (=10/week) or one binge-drinking episode per week.
- •25. Consuming cannabis or its derived products more than two times per week
- •26. Consuming illicit substances (not prescribed by physicians) once or more per week
- •27. History of using anti-depressant medications for conditions other than depression e.g., smoking cessation in the past 5 years
- •28. History of or planned bariatric surgery within 6 months of pharmacogenomic testing
- •29. Participants not willing to sign the informed consent
- •30. Participants unable to respond to standard questionnaires in English
研究者
相似试验
进行中（未招募）
不适用
Assessment of Quality of life in Chronic lung diseaseCTRI/2014/08/004848Suhaj A260
招募中
不适用
pharmacoGenomic gUIDEd persONalized MEDicine: clinical settingNL-OMON56044Maasstadziekenhuis100
尚未招募
不适用
Evaluation of the pharmacist's performance in the care of hospital discharge patients in the cardiology unit of a teaching hospital in Espírito SantoCardiovascular DiseasesPatient DischargeEvidence-Based Pharmacy PracticePharmacy Service, HospitalN02.421.668RBR-10hdj2bgeonardo Coutinho Ribeiro
已完成
不适用
Study for personalized medicine based on pharmacokinetics and pharmacodynamics concerned with therapeutic drug of nontuberculous mycobacterium.JPRN-UMIN000020406Center for Infectious Disease and Infection Control10
招募中
不适用
Take it Personal!+: a personalized treatment for substance use disorder in people with mild intellectual disability and borderline intellectual functioningNL-OMON26987ZonMw Mr. F. Couvee stichting15